$150.00 – $1,800.00
BUY SYNTHACAINE ONLINE
Synthacaine chemical has had a rather bad reputation in the research industry. Subsequently, this is because many companies are selling very low quality samples of it. We work closely with a reputable laboratory to ensure that our synthacaine is at least 98% pure. This is a very strong and popular stimulant. We do not release the exact formulation of this product. This is because it is a proprietary blend but the main ingredient is methiopropamine.
Methiopropamine (MPA, 1-(thiophen-2-yl)-2-methylaminopropane) belongs to the novel psychoactive substances (NPS), which have emerged on the drug market over recent years. MPA was first detected as a recreational drug in Europe in January 2011 when it was reported by Finland to the European Monitoring Center for Drugs and Drug Addiction Early warning system (1). As for all NPS, MPA is available through the Internet (at low cost) either under its chemical name, or under “brand” names such as “Blow”, “Slush Eric” or “synthacaine”, which is a slang contraction of “synthetic” and “cocaine”, sometimes publicized as “legal cocaine”. There is obviously no assurance that the substance purchased is really the expected one and this is further complicated when a “brand” name is used. For instance, not every preparation sold as “synthacaine” contains MPA. Previously, camfetamine alone or blends such as MPA with benzocaine or MPA with 2-aminoindane have been identified in samples of “synthacaine” (2), but also MAM-22011, a synthetic cannabinoid, has been found in such preparations (3).
In many countries MPA remains unregulated which allows users to circumvent laws to obtain a “legal high”. However, being structurally related to metamfetamine it is highly probable that MPA is associated with significant adverse effects. There are limited data on MPA toxicity in the literature, with only two published cases of acute toxicity related to the self-reported use of MPA (4, 5). Reported adverse effects of MPA use are mostly anecdotal user reports on web forums; tachycardia, insomnia and chest pain. This needs to be interpreted with caution since there is variability in the content of NPS purchased over the Internet or from high-street suppliers (6). It is therefore important from both a clinical and law enforcement perspective that the description of the acute toxicological profile associated with the use of NPS is supported by toxicological analytical screening, especially when the substance really taken by the patient is different from the substance supposed to have been ingested.
The authors describe here a case of MPA intoxication after “synthacaine” use